Telomerase reverse transcriptase subunit immunoreactivity - A marker for high-grade prostate carcinoma

被引:30
作者
Iczkowski, KA
Pantazis, CG
McGregor, DH
Wu, YP
Tawfik, OW
机构
[1] Vet Adm Med Ctr, Pathol & Lab Med Serv 113, Gainesville, FL 32608 USA
[2] Univ Florida, Dept Pathol Immunol & Lab Med, Gainesville, FL 32611 USA
[3] Vet Adm Med Ctr, Pathol & Lab Med Serv, Kansas City, MO 64128 USA
[4] Univ Kansas, Dept Pathol, Kansas City, KS USA
关键词
telomerase; human telomerase reverse transcriptase; prostate carcinoma; high-grade prostatic intraepithelial neoplasia; immunohistochemistry;
D O I
10.1002/cncr.10988
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
BACKGROUND. Telomerase, a ribonucleoprotein complex that maintains telomeric DNA, has been detected in 67-93% of prostate carcinomas by telomeric repeat-amplification protocol assay (involving polymerase chain reaction). One study used in situ hybridization in nine patients; however, to date, no immunohistochemical results have been published. METHODS. From two hospitals, the authors compiled data on 62 patients who underwent prostatectomy from January 1996 to May 2001. Representative tissue sections were immunostained with a polyclonal antibody to telomerase reverse transcriptase (TERT), the catalytic subunit of telomerase. Staining was evaluated by two observers and was correlated with grade, stage, and biochemical failure. There were 28 sections from low-grade to intermediate-grade tumors (Gleason score, 3-6), 14 sections with a Gleason score of 3 + 4 = 7, 9 sections with a Gleason score of 4 + 3 = 7, and 11 sections from high-grade tumors (Gleason score, 8-10). RESULTS. From low-grade to high-grade tumors, the four groups described above disclosed nuclear reactivity in 64%, 100%, 100%, and 100% of sections, respectively. Mean percentages of 5%, 15%, 40%, and 51% of nuclei were reactive in the respective groups (P < 0.0001) with intratumoral heterogeneity. The percent of reactive tumor nuclei was not correlated with pathologic stage (P = 0.32) or margin status (P = 0.35). The basal cell layer in sections of high-grade prostatic intraepithelial neoplasia (HGPIN) and benign/atrophic acini was reactive; secretory cells were reactive in 13 of 34 HGPIN foci (38%) in 1-20% of nuclei and were never reactive in benign acini. Lymphocytes and skeletal muscle were reactive. Weak, nonspecific, cytoplasmic staining was noted in benign and tumor acini. CONCLUSIONS. Like cytokeratin 34betaE12, nuclear anti-TERT reactivity is a basal cell marker in nonneoplastic prostatic acini. Anti-TERT reactivity is acquired by secretory cells in tumorigenesis, but consistent reactivity is restricted to high-grade carcinoma (Gleason primary pattern greater than or equal to 4). This histologic evidence suggests that higher grade tumors have maximally activated telomerase and may be most responsive to antitelomerase therapy. Cancer 2002;95:2487-93. (C) 2002 American Cancer Society.
引用
收藏
页码:2487 / 2493
页数:7
相关论文
共 34 条
  • [1] [Anonymous], 1997, TNM CLASSIFICATION M
  • [2] Beach R, 2002, MODERN PATHOL, V15, p155A
  • [3] BRAWER MK, 1985, CANCER RES, V45, P3663
  • [4] Caldarera E, 2000, PROSTATE, V45, P267, DOI 10.1002/1097-0045(20001101)45:3<267::AID-PROS10>3.0.CO
  • [5] 2-F
  • [6] Prognostic significance of Gleason score 3+4 versus Gleason score 4+3 tumor at radical prostatectomy
    Chan, TY
    Partin, AW
    Walsh, PC
    Epstein, JI
    [J]. UROLOGY, 2000, 56 (05) : 823 - 827
  • [7] Engelhardt M, 1997, CLIN CANCER RES, V3, P1849
  • [8] THE RNA COMPONENT OF HUMAN TELOMERASE
    FENG, JL
    FUNK, WD
    WANG, SS
    WEINRICH, SL
    AVILION, AA
    CHIU, CP
    ADAMS, RR
    CHANG, E
    ALLSOPP, RC
    YU, JH
    LE, SY
    WEST, MD
    HARLEY, CB
    ANDREWS, WH
    GREIDER, CW
    VILLEPONTEAU, B
    [J]. SCIENCE, 1995, 269 (5228) : 1236 - 1241
  • [9] Localization of telomerase hTERT protein and hTR in benign mucosa, dysplasia, and squamous cell carcinoma of the cervix
    Frost, M
    Bobak, JB
    Gianani, R
    Kim, N
    Weinrich, S
    Spalding, DC
    Cass, LG
    Thompson, LC
    Enomoto, T
    Uribe-Lopez, D
    Shroyer, KR
    [J]. AMERICAN JOURNAL OF CLINICAL PATHOLOGY, 2000, 114 (05) : 726 - 734
  • [10] Expression of mouse telomerase reverse transcriptase during development, differentiation and proliferation
    Greenberg, RA
    Allsopp, RC
    Chin, L
    Morin, GB
    DePinho, RA
    [J]. ONCOGENE, 1998, 16 (13) : 1723 - 1730